CSL’s outgoing chairman Brian McNamee has defended the $41 million remuneration package for the company’s incoming CEO, Deborah Waterhouse, describing it as comparable to a “transfer fee” in elite sports leagues. The package includes $15 million to compensate for bonuses and equity Ms. Waterhouse is expected to forfeit by leaving her previous employer, GlaxoSmithKline (GSK).
Dr. McNamee, who will step down from the board at the end of March but remain involved for the first month of Ms. Waterhouse’s tenure, said the package reflects CSL’s intention to secure a “world-class” executive capable of maintaining the company’s competitive position. “If CSL wanted to compete in the Premier League, it had to cover the bonuses she was expected to forgo,” he stated, emphasizing that the payout compensates for GSK awards earned through her work there rather than representing additional compensation.
Under the terms disclosed last week, Ms. Waterhouse’s total potential remuneration could reach up to approximately A$42 million (£21.96 million), with a base salary of £1.5 million and long-term incentives that may amount to as much as 500 percent of the base. The buyout of forfeited GSK awards was valued at £7.7 million. Ms. Waterhouse, a veteran of GSK who previously led its Australian operations, will be based in London but will frequently visit CSL offices in Australia and the United States.
Ms. Waterhouse’s appointment follows a turbulent period for CSL, which saw the departure of former CEO Paul McKenzie earlier this year amid profit warnings, a failed clinical trial, and a sharp decline in its share price. Gordon Naylor, a former chief financial officer and interim CEO since February, is set to become the company’s chairman in early 2027.
At the company’s annual general meeting, shareholders reflected on Dr. McNamee’s tenure, recognizing his role in transforming CSL from a government-linked entity into a global biopharmaceutical leader. However, some investors expressed concerns about recent challenges, particularly the $16.4 billion acquisition of Swiss renal treatment company Vifor Pharma in late 2022, half of which was later written down. Additional financial setbacks included a costly unsuccessful heart drug trial and volatility in CSL’s stock, which more than halved between 2024 and 2026 before recovering to around $195 per share.
Dr. McNamee acknowledged these difficulties, attributing them partly to broader market volatility influenced by global investment trends and automated trading. He also suggested that future growth might come through smaller, more targeted acquisitions rather than large-scale deals, leaving the strategy open for the incoming CEO and new chairman to determine.